Product Name:
Cot
Product Number:
ab-nk041-2
Target Full Name: Osaka thyroid oncogene protein-serine kinase (Tpl2); Mitogen-activated protein kinase kinase kinase 8
Target Alias: FLJ10486; M3K8; MAP3K8; Tpl2; TPL2; TPL-2; tumour progression locus 2; Cot; ESTF; EST; Tpl-2; c-Cot; ENSG00000107968
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK042
Antibody Target Type: Pan-specific
Protein UniProt: P41279
Protein SigNET: P41279
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Cot (MAP3K8, TPL2) sequence peptide
Antibody Immunogen Sequence: MEYMSTGSDNKEEIDC
Antibody Immunogen Description: Corresponds to amino acid residues M1 to D15; N-terminus
Production Method: Corresponds to amino acid residues M1 to D15; N-terminus
Antibody Modification: Protein kinase pan-specific antibody
Storage Buffer: 100 mM Tris-glycine, pH 7.0
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months, but either 0.1% sodium azide or 0.05% Thimerasol should be added. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with recombinant human Cot expressed in E. coli as a glutathione S transferase fusion protein.
Antibody Species Reactivity: Human; Mouse; Rat
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 52-57 kDa.
Antibody Cross Reactivity: Cross-reacts with an unidentified 30 kDa protein in rat skeletal muscle.
Related Product 1: Cot-CT (Cot-2) pan-specific antibody (Cat. No.: AB-NK042-2)
Related Product 2: Cot-pS334 phosphosite-specific antibody (Cat. No.: AB-PK585)
Related Product 3: Cot (Cot-1) pan-specific antibody (Cat. No.: AB-NK042-1)
Scientific Background: Cot (TPL2, MAP3K8) is a protein-serine/threonine kinase of the STE group and STE-Unique family. It is essential in the TLR4 (recognizing LPS) MAPK/ERK-mediated response in the production of pro-inflammatory cytokines. Catalytic activity of Cot is lost with the K167R, or D270A mutations. IL-1 stimulated activity is decreased with S62A. This mutation will also inhibit IL-1 stimulated phosphorylation of T290 along with MEK phosphorylation when associated with A400. Full inhibition of IL-1 induced MEK phosphorylation and partial inhibition of autophosphorylation can occur with a T290A mutation. Partial inhibition of MEK phosphorylation and autophosphorylation has occurred with a T290A or T290E mutation. Partial impairment of MEK phosphorylation induced by IL-1 has been observed with a S400A mutation. When Cot is associated with A62, a complete loss of T290 and MEK phosphorylation occurs with a S400A mutation.
